Guardant Health Surges 13% on 197% Volume Spike Ranks 269th in Market Activity

On August 7, 2025, Guardant Health (GH) surged 13.01% to $51.50, with a trading volume of $0.43 billion—a 197.6% increase from the prior day—ranking 269th in market activity. The stock’s recent momentum reflects a mix of strategic partnerships and robust earnings performance.

Guardant expanded its cancer screening access through a collaboration with the American Cancer Society, aiming to enhance health equity. Additionally, the company announced a partnership with actor James Van Der Beek to promote its FDA-approved Shield™ blood test for colorectal cancer. These initiatives align with Guardant’s focus on broadening early detection solutions.

Financially, Guardant reported Q2 2025 revenue of $232.1 million, a 31% year-over-year increase, surpassing analyst expectations. The firm raised its full-year revenue guidance to $920 million, driven by strong demand for its liquid biopsy tests and expanded market access. Despite a non-GAAP loss of $0.44 per share, the results outperformed estimates, signaling improving operational efficiency.

The strategy of purchasing the top 500 stocks by daily trading volume and holding for one day yielded a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the potential of liquidity-focused strategies in volatile markets, though risks remain for short-term traders.